Session XIX: Presentation of Selected Abstracts on GI Cancer

Chair(s)

• 

  Josep Tabernero, MD

  Vall d’Hebron University Hospital
  Barcelona, Spain
• 

  Pierre Laurent-Puig, MD. PhD

  Université de Paris
  PARIS, France

Presentations:

• 08:15 – 08:23

  SO-31: Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: an expanded dataset
  

  Abstract Presenter: Elena Garralda, MD – Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology
• 08:23 – 08:31

  SO-32: Entrectinib in NTRK fusion-positive gastrointestinal cancers: updated integrated analysis
  

  Abstract Presenter: Ignacio Garrido-Laguna
• 08:31 – 08:39

  SO-33: Neoadjuvant immunotherapy in gastrointestinal tumors with mismatch repair deficiency: An institutional analysis
  

  Abstract Presenter: Sakti Chakrabarti
• 08:39 – 08:49

  Discussant: SO-31, SO-32, SO-33
  

  Discussant: Juan Manuel O'Connor, MD, MSc – Instituto Alexander Fleming
• 08:49 – 08:57

  LBA SO-34: Impact of BRAF-V600E mutation on immunologic characteristics of the tumor microenvironment (TME) and associated genomic alterations in patients with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) colorectal cancer (CRC)
  

  Abstract Presenter: Mohamed E. Salem, MD – Levine Cancer Institute
• 08:57 – 09:05

  SO-35: T-cell abundance measured by immunoSEQ predicts overall survival in colorectal cancer
  

  Abstract Presenter: Stephen Gruber
• 09:05 – 09:13

  SO-36: An immune-related gene expression profile predicts the efficacy of adding atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer: a translational analysis of the phase II randomized AtezoTRIBE study
  

  Abstract Presenter: Carlotta Antoniotti
• 09:13 – 09:25

  Discussant: LBA SO-34, SO-35, SO-36
  

  Discussant: Pierre Laurent-Puig, MD. PhD – Université de Paris